Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Expands By 5.3%

Humacyte, Inc. (NASDAQ:HUMA) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 3,980,000 shares, an increase of 5.3% from the March 15th total of 3,780,000 shares. Based on an average daily volume of 968,700 shares, the short-interest ratio is currently 4.1 days. Approximately 4.6% of the shares of the stock are short sold.

Analyst Ratings Changes

Several analysts have commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a research note on Tuesday, March 26th. Benchmark reaffirmed a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Monday, March 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research note on Monday, April 1st.

Humacyte Stock Up 4.5 %

Shares of NASDAQ HUMA opened at $3.00 on Tuesday. Humacyte has a 52-week low of $1.96 and a 52-week high of $5.60. The firm has a fifty day moving average of $3.53 and a 200-day moving average of $2.97. The company has a debt-to-equity ratio of 1.20, a current ratio of 4.52 and a quick ratio of 4.52.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the firm earned ($0.21) EPS. On average, sell-side analysts predict that Humacyte will post -0.9 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Asset Management Americas Inc. lifted its holdings in shares of Humacyte by 17.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 15,947 shares of the company’s stock valued at $51,000 after acquiring an additional 2,347 shares in the last quarter. Legal & General Group Plc lifted its holdings in Humacyte by 24.7% in the 2nd quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock worth $55,000 after buying an additional 3,364 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in Humacyte by 16.2% in the 1st quarter. Susquehanna International Group LLP now owns 31,367 shares of the company’s stock worth $97,000 after buying an additional 4,372 shares in the last quarter. UBS Group AG lifted its holdings in Humacyte by 92.0% in the 3rd quarter. UBS Group AG now owns 9,827 shares of the company’s stock worth $32,000 after buying an additional 4,710 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in Humacyte by 16.3% in the 2nd quarter. Osaic Holdings Inc. now owns 33,985 shares of the company’s stock worth $97,000 after buying an additional 4,775 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).